Literature DB >> 10514287

Antitumor benzothiazoles. 8. Synthesis, metabolic formation, and biological properties of the C- and N-oxidation products of antitumor 2-(4-aminophenyl)benzothiazoles.

E Kashiyama1, I Hutchinson, M S Chua, S F Stinson, L R Phillips, G Kaur, E A Sausville, T D Bradshaw, A D Westwell, M F Stevens.   

Abstract

2-(4-Aminophenyl)benzothiazoles 1 and their N-acetylated forms have been converted to C- and N-hydroxylated derivatives to investigate the role of metabolic oxidation in the mode of action of this series of compounds. 2-(4-Amino-3-methylphenyl)benzothiazole (1a, DF 203, NSC 674495) is a novel and potent antitumor agent with selective growth inhibitory properties against human cancer cell lines. Very low IC(50) values (<0.1 microM) were encountered in the most sensitive breast cancer cell lines, MCF-7 and T-47D, whereas renal cell line TK-10 was weakly inhibited by 1a. Cell lines from the same tissue origin, MDA-MB-435 (breast), CAKI-1 (renal), and A498 (renal), were insensitive to 1a. Accumulation and metabolism of 1a were observed in sensitive cell lines only, with the highest rate of metabolism occurring in the most sensitive MCF-7 and T-47D cells. Thus, differential uptake and metabolism of 1a by cancer cell lines may underlie its selective profile of anticancer activity. A major metabolite in these sensitive cell lines has been identified as 2-(4-amino-3-methylphenyl)-6-hydroxybenzothiazole (6c). Hydroxylation of 1a was not detected in the homogenate of previously untreated MCF-7, T-47D, and TK-10 cells but was readily observed in homogenates of sensitive cells that were pretreated with 1a. Accumulation and covalent binding of [(14)C]1a derived radioactivity was observed in the sensitive MCF-7 cell line but not in the insensitive MDA-MB-435 cell line. The mechanism of growth inhibition by 1a, which is unknown, may be dependent on the differential metabolism of the drug to an activated form by sensitive cell lines only and its covalent binding to an intracellular protein. However, the 6-hydroxy derivative 6c is not the 'active' metabolite since, like all other C- and N-hydroxylated benzothiazoles examined in this study, it is devoid of antitumor properties in vitro.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10514287     DOI: 10.1021/jm990104o

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  24 in total

1.  Base catalyzed multicomponent synthesis of spiroheterocycles with fused heterosystems.

Authors:  Anand Kumar Arya; Mahendra Kumar
Journal:  Mol Divers       Date:  2011-03-20       Impact factor: 2.943

2.  DNA Binding, Cleavage and Antibacterial Activity of Mononuclear Cu(II), Ni(II) and Co(II) Complexes Derived from Novel Benzothiazole Schiff Bases.

Authors:  Narendrula Vamsikrishna; Marri Pradeep Kumar; Somapangu Tejaswi; Aveli Rambabu
Journal:  J Fluoresc       Date:  2016-05-11       Impact factor: 2.217

3.  Characterization of the 4-(benzothiazol-2-yl)phenylnitrenium ion from a putative metabolite of a model antitumor drug.

Authors:  Mrinal Chakraborty; Kyoung Joo Jin; Stephen A Glover; Michael Novak
Journal:  J Org Chem       Date:  2010-08-06       Impact factor: 4.354

4.  Highly efficient water-mediated approach to access benzazoles: metal catalyst and base-free synthesis of 2-substituted benzimidazoles, benzoxazoles, and benzothiazoles.

Authors:  Manju Bala; Praveen Kumar Verma; Deepika Sharma; Neeraj Kumar; Bikram Singh
Journal:  Mol Divers       Date:  2015-03-11       Impact factor: 2.943

5.  Benzothiazole bipyridine complexes of ruthenium(II) with cytotoxic activity.

Authors:  Caitriona B Spillane; Nicholas C Fletcher; Sandra M Rountree; Hendrik van den Berg; Severine Chanduloy; Joy L Morgan; F Richard Keene
Journal:  J Biol Inorg Chem       Date:  2007-05-26       Impact factor: 3.358

6.  Chemistry of ring-substituted 4-(benzothiazol-2-yl)phenylnitrenium ions from antitumor 2-(4-aminophenyl)benzothiazoles.

Authors:  Yang Zhang; Mrinal Chakraborty; Christian G Cerda-Smith; Ryan N Bratton; Natalie E Maurer; Ethan M Senser; Michael Novak
Journal:  J Org Chem       Date:  2013-07-01       Impact factor: 4.354

7.  Development of novel apoferritin formulations for antitumour benzothiazoles.

Authors:  Alastair F Breen; Geoffrey Wells; Lyudmila Turyanska; Tracey D Bradshaw
Journal:  Cancer Rep (Hoboken)       Date:  2019-01-16

8.  Variations in Mre11/Rad50/Nbs1 status and DNA damage-induced S-phase arrest in the cell lines of the NCI60 panel.

Authors:  Kristen M Garner; Alan Eastman
Journal:  BMC Cancer       Date:  2011-05-27       Impact factor: 4.430

9.  The role of aryl hydrocarbon receptor and crosstalk with estrogen receptor in response of breast cancer cells to the novel antitumor agents benzothiazoles and aminoflavone.

Authors:  Mariana A Callero; Andrea I Loaiza-Pérez
Journal:  Int J Breast Cancer       Date:  2011-09-22

10.  Antitumour 2-(4-aminophenyl)benzothiazoles generate DNA adducts in sensitive tumour cells in vitro and in vivo.

Authors:  C-O Leong; M Gaskell; E A Martin; R T Heydon; P B Farmer; M C Bibby; P A Cooper; J A Double; T D Bradshaw; M F G Stevens
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.